22911-39-3Relevant articles and documents
PROCESS FOR THE MANUFACTURE OF OMEGA NITROOXY-1-ALKANOLS
-
Page/Page column 10-11; 12, (2020/05/06)
The invention relates to a process for the preparation of ω-nitroxyC3-10 alkane-1-ols comprising the nitration of an α,ω-C 3-10 alkanediol with a nitration agent, optionally in the presence of a nitrite trapping agent, characterized in that the nitration agent is a mixture consisting of 50 to 75 wt.-% of nitric acid in water wherein the nitric acid is used in an amount selected in the range from 0.5 to 5 mol equivalents based on the α,ω--C3-10alkanediols, and wherein the nitration is carried out at a temperature selected in the range from 65 - 100°C.
Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy
Ren, Shen-Zhen,Wang, Zhong-Chang,Zhu, Dan,Zhu, Xiao-Hua,Shen, Fa-Qian,Wu, Song-Yu,Chen, Jin-Jin,Xu, Chen,Zhu, Hai-Liang
, p. 909 - 924 (2018/08/31)
A series of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy were designed, synthesized and biologically evaluated. Among them, compound 7l displayed the most potent inhibitory against COX-2 (IC50 = 0.82 μM) and antiproliferative activities against Hela cells (IC50 = 0.34 μM) compared with Celecoxib (IC50 = 0.38 and 7.91 μM). The further mechanistic studies revealed that 7l could induce apoptosis of Hela cells by mitochondrial depolarization and the antiproliferative activities of 7l were positively correlated with the levels of intracellular NO release in Hela cells. Most notably, 7l could dramatically suppress tumor growth in Hela cells xenografted mouse model. In summary, compound 7l may be promising candidates for cancer therapy.
QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE
-
Page/Page column 40, (2014/11/11)
The present invention relates to nitric oxide donor compounds having a quinone based structure of formula (I), wherein R1 to R6, n, m and p are as defined in claim 1, compositions thereof and said compounds for use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.